在IDWeek 2024上,Invivyd 发布了关于PEMGARDA COVID-19 暴露前预防的第3期CANOPY研究数据. Invivyd presents Phase 3 CANOPY study data on PEMGARDA COVID-19 pre-exposure prophylaxis at IDWeek 2024.
生化制药公司Invivivyd将提供10月16日至19日在洛杉矶2024年IDWeek的单克隆抗体PEMGARDA(Pemvibart)的数据。 Biopharmaceutical company Invivyd will present data on its monoclonal antibody PEMGARDA (pemivibart) at IDWeek 2024 in Los Angeles from October 16-19. 重点将放在CANOPY第三阶段的研究上,评估PEMGARDA相对于COVID-19的有效性。 The focus will be on the Phase 3 CANOPY study, assessing PEMGARDA's effectiveness against COVID-19. 经FDA授权应急使用,PEMGARDA用于免疫功能低下个体的暴露前预防,但不用于治疗COVID-19. Authorized by the FDA for emergency use, PEMGARDA is intended for pre-exposure prophylaxis in immunocompromised individuals but is not for treating COVID-19. 不良事件包括高度敏感反应和感染。 Adverse events include hypersensitivity reactions and infections.